210 related items for PubMed ID: 25335326
1. [Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
Guo ZA, Yu CJ, Liu G, Meng FC, Li Y, Peng SL.
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1047-52. PubMed ID: 25335326
[Abstract] [Full Text] [Related]
2. [Treatment of diabetic nephropathy by integrative medicine: a multi-center prospective cohort study].
Li Q, Zhang HM, Fei YT.
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Mar; 32(3):317-21. PubMed ID: 22686074
[Abstract] [Full Text] [Related]
3. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
Yan M, Wen Y, Yang L, Wu X, Lu X, Zhang B, Huang W, Li P.
Trials; 2016 May 23; 17(1):259. PubMed ID: 27216240
[Abstract] [Full Text] [Related]
4. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B, Zhang Y, Liu G, Guan GJ, Hou XH, Li XG, Liu JL.
Zhonghua Yi Xue Za Zhi; 2008 Feb 26; 88(8):540-5. PubMed ID: 18649770
[Abstract] [Full Text] [Related]
5. [Clinical observation on the disease course of chronic renal failure intervened by qudu granule].
Guo HA, Zhang AZ, Xu BX.
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Oct 26; 32(10):1340-4. PubMed ID: 23163142
[Abstract] [Full Text] [Related]
6. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Zhao XM, Zhang Y, He XH, Chen HD, Wang ZF, Guo J, Wang XM, Gao ZZ, Wang JP, Liu W, Zhao LH, Tong XL.
Trials; 2018 Mar 27; 19(1):200. PubMed ID: 29587863
[Abstract] [Full Text] [Related]
7. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
Wang M, Wang Z, Zhou J, Sun W, Wang Y, Han M, Yang H, Liu WJ, Wang Y.
Trials; 2018 Jul 17; 19(1):389. PubMed ID: 30016983
[Abstract] [Full Text] [Related]
8. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J, Machida Y, Iwai T, Iguchi T, Kamada Y, Naganuma T, Kumada N, Kim T, Kawashima H, Nakatani T.
J Nephrol; 2011 Jul 17; 24(4):515-21. PubMed ID: 21240871
[Abstract] [Full Text] [Related]
9. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Estacio RO, Coll JR, Tran ZV, Schrier RW.
Am J Hypertens; 2006 Dec 17; 19(12):1241-8. PubMed ID: 17161769
[Abstract] [Full Text] [Related]
10. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T.
Kidney Int; 2006 Jul 17; 70(1):151-6. PubMed ID: 16710356
[Abstract] [Full Text] [Related]
11. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL.
Trials; 2019 Dec 21; 20(1):756. PubMed ID: 31864393
[Abstract] [Full Text] [Related]
12. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, Li P.
BMC Complement Altern Med; 2016 Jul 26; 16():246. PubMed ID: 27460780
[Abstract] [Full Text] [Related]
13. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
Hypertens Res; 2007 Jun 26; 30(6):529-33. PubMed ID: 17664856
[Abstract] [Full Text] [Related]
14. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
Nephrology (Carlton); 2015 Feb 26; 20(2):77-84. PubMed ID: 25358874
[Abstract] [Full Text] [Related]
15. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
J Hypertens; 2000 Jan 26; 18(1):89-95. PubMed ID: 10678548
[Abstract] [Full Text] [Related]
16. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
Clin Ther; 2005 May 26; 27(5):578-87. PubMed ID: 15978306
[Abstract] [Full Text] [Related]
17. [Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet].
Li BY, Peng H, Xiong DL, Yi J, Chen H.
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Feb 26; 35(2):142-6. PubMed ID: 25881456
[Abstract] [Full Text] [Related]
18. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.
PLoS One; 2015 Feb 26; 10(5):e0126027. PubMed ID: 25938778
[Abstract] [Full Text] [Related]
19. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial.
Wang YJ, He LQ, Sun W, Lu Y, Wang XQ, Zhang PQ, Wei LB, Cao SL, Yang NZ, Ma HZ, Gao J, Li P, Tao XJ, Yuan FH, Li J, Yao C, Liu X.
J Ethnopharmacol; 2012 Feb 15; 139(3):757-64. PubMed ID: 22178174
[Abstract] [Full Text] [Related]
20. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH, Hou FF, Zhang X, Liu QF.
Zhonghua Nei Ke Za Zhi; 2005 Aug 15; 44(8):592-6. PubMed ID: 16194413
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
